We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Vismodegib Granted FDA Approval for Treatment of Basal Cell Carcinoma.
- Abstract
The article reports that the U.S. Food and Drug Administration (FDA) has approved Vismodegib for basal cell carcinoma treatment. It states that the medication, manufactured by Genetech, is the first drug for basal cell carcinoma to be granted an approval. It cites a study involving 96 patients, in which the drug has cured lesions in nearly half of the patients in the study. It discusses some adverse effects of the drug such as muscle spasms, alopecia and nausea.
- Subjects
ANTINEOPLASTIC agents; BASAL cell carcinoma; GROWTH factors; UNITED States. Food &; Drug Administration; DRUG approval
- Publication
Oncology (08909091), 2012, Vol 26, Issue 2, p174
- ISSN
0890-9091
- Publication type
Article